Summary
To determine whether long-term adriamycin (ADM) infusions resulted in cellular ADM concentrations at least comparable to those observed after bolus injections, ADM cellular and plasma concentrations were measured in 18 patients with leukemia. ADM was administered at 30 mg/m2 per day for 3 days, either as bolus injections or as 4-, 8-, or 72-h infusions. Negligible accumulation of plasma ADM was observed. Peak plasma ADM concentrations after bolus injections were 1640±470 ng/ml (n=7). Maximum levels were 176±34 ng/ml during 4-h infusion (n=5); 85±50 ng/ml during 8-h infusion (n=4); and 47±5 ng/ml (n=2) after 72-h infusion. ADM concentrations in nucleated blood and bone marrow cells correlated well (r=0.82, n=47). ADM accumulated in leukemic cells up to 30–100 times the plasma concentrations. The shorter the administration time-span, the higher the peak leukemic cell concentration and the greater the loss of drug immediately after the end of the administration. The final cellular ADM half-life was approximately 85–110 h. After long-term infusion and bolus injection of the same dose, similar areas under the curve for plasma or leukemic blast cell ADM concentrations were attained. Since comparable therapeutic efficacy was observed in all regimens, the antileukemic effect appeared not to be related to the peak plasma concentrations, while acute toxicity phenomena decreased with increasing duration of the infusion. Long-term ADM infusion deserves more attention in the treatment of patients with anthracyclines.
Similar content being viewed by others
References
Andersson B, Beran M, Peterson C, Tribukait B (1982) Significance of cellular pharmacokinetics for the toxic effects of daunorubicin. Cancer Res 42: 178
Barlogie B, Smith L, Alexenian R (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310: 1353
Casazza AM (1976) Experimental evaluation of anthracycline analogs. Cancer Treat Rep 63: 835
DeGregorio MW, Holleran WM, Macher BA, Linker CA, Wilbur JR (1984) Kinetics and sensitivity of daunorubicin in patients with acute leukemia. Cancer Chemother Pharmacol 13: 230
Egorin MJ, Clawson RE, Cohen JL, Ross LA, Bachur NR (1980) Cytofluorescence localization of anthracycline antibiotics. Cancer Res 40: 4669
Eichholtz-Wirth H (1980) Dependence of the cytostatic effect of Adriamycin on drug concentration and exposure time in vitro. Br J Cancer 41: 886
Eksborg S, Strandler H, Edsmyr F, Naslund I, Tahvanianen P (1985) Pharmacokinetic study of i.v. infusions of adriamycin. Eur J Clin Pharmacol 28: 205
Freireich EJ (1984) The role of adriamycin in the treatment of adult acute leukemia. Excerpta Medica Int Congr Ser 629: 3
Garnick MB, Weiss GR, Steele GD, Israel M, Schade D, Sack MJ, Frei E (1983) Clinical evaluation of long-term continuous-infusion doxorubicin. Cancer Treat Rep 67: 133
Glazer RI, Hartman KD, Richardson CL (1982) Cytokinetic and biochemical effects of 5-iminodaunorubicin in human colon carcinoma in culture. Cancer Res 42: 117
Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE (1983) Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res 43: 3417
Holdrinet RSG, Egmond J van, Wessels JMC, Haanen C (1980) A method for quantification of peripheral blood admixture in bone marrow aspirates. Exp Hemat 8: 103
Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Int Med 96: 133
Lewis JP, Meyer FJ, Tanaken L (1985) Daunomycin administration by continuous infusion is effective in the treatment of acute nonlymphocytic leukemia. Br J Haematol 61: 261
Lum BL, Svec JM, Torti FM (1985) Doxorubicin: alteration of dose scheduling as a means of reducing cardiotoxicity. Drug Intell Clin Pharmacol 19: 258
Nguyen-Noc T, Vrignaud P, Robert J (1984) Cellular pharmacokinetics of doxorubicin in cultured mouse sarcoma cells originating from autochtonous tumors. Oncology 41: 55
Peterson C, Paul C (1983) Pharmacokinetics of doxorubicin and daunorubicin in the treatment of acute leukemia. In: Hansen HH (ed) Anthracyclines and cancer therapy. Excerpta Medica, Amsterdam, p 7
Ritch PS, Occhipinti SJ, Skramstad KS, Shackney SE (1982) Increased relative effectiveness of doxorubicin against slowly proliferating sarcoma 180 cells after prolonged drug exposure. Cancer Treat Rep 66: 1159
Speth PAJ, Linssen PCM, Boezeman JBM, Wessels JMC, Haanen C (1985) Quantitation of anthracyclines in human hematopoietic cell subpopulations by flow cytometry correlated with high pressure liquid chromatography. Cytometry 6: 143
Speth PAJ, Linssen PCM, Boezeman JBM, Wessels JMC, Haanen C (1986) Rapid quantitative determination of four anthracyclines and their main metabolites in human nucleated hematopoietic cells. J Chromatogr 377: 415
Speth PAJ, Linssen PCM, Boezeman JBM, Wessels JMC, Haanen C (1987) Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 hours infusion. Cancer Chemother Pharmacol 20: 311–315
Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publishers, Hamilton
Author information
Authors and Affiliations
Additional information
Supported by the Queen Wilhelmina Foundation (The Netherlands Cancer Foundation, grant SNUKC 82-7), The Ank van Vlissingen Foundation and The Maurits and Anna de Kock Foundation
Rights and permissions
About this article
Cite this article
Speth, P.A.J., Linssen, P.C.M., Boezeman, J.B.M. et al. Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. Cancer Chemother. Pharmacol. 20, 305–310 (1987). https://doi.org/10.1007/BF00262581
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00262581